

12-19-05

12/19/05



PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<h1 style="text-align: center;">TRANSMITTAL FORM</h1> <p style="text-align: center;">(to be used for all correspondence after initial filing)</p>		Application Number	10/828,481-Conf. #4860
		Filing Date	April 20, 2004
		First Named Inventor	Carl H. JUNE et al.
		Art Unit	1632
		Examiner Name	D. T. Nguyen
Total Number of Pages in This Submission	5	Attorney Docket Number	36119.140US3/AM100528


ENCLOSURES (Check all that apply)

<input checked="" type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Reply to Missing Parts/Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input type="checkbox"/> Other Enclosure(s) (please identify below):
<div style="border: 1px solid black; padding: 5px; min-height: 50px;"> Remarks </div>		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	WILMER CUTLER PICKERING HALE AND DORR LLP		
Signature	<i>Colleen Superko</i>		
Printed name	Colleen Superko		
Date	December 15, 2005	Reg. No.	39,850

Express Mail Label No. EV621477199US Dated: December 16, 2005




Effective on 12/08/2004. Fees pursuant to the Consolidated Appropriations Act, 2005 (H.R. 4818).		Complete if Known	
FEE TRANSMITTAL For FY 2005		Application Number	10/828,481-Conf. #4860
		Filing Date	April 20, 2004
		First Named Inventor	Carl H. JUNE et al.
		Examiner Name	D. T. Nguyen
		Art Unit	1632
<input type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27		Attorney Docket No.	36119.140US3/AM100528
TOTAL AMOUNT OF PAYMENT		(\$)	180.00

METHOD OF PAYMENT (check all that apply)	
<input type="checkbox"/> Check	<input type="checkbox"/> Credit Card
<input type="checkbox"/> Money Order	<input type="checkbox"/> None
<input type="checkbox"/> Other (please identify): _____	
<input checked="" type="checkbox"/> Deposit Account	Deposit Account Number: <u>08-0219</u> Deposit Account Name: <u>Wilmer Cutler Pickering Hale and Dorr LLP</u>
For the above-identified deposit account, the Director is hereby authorized to: (check all that apply)	
<input checked="" type="checkbox"/> Charge fee(s) indicated below	<input type="checkbox"/> Charge fee(s) indicated below, except for the filing fee
<input checked="" type="checkbox"/> Charge any additional fee(s) or underpayment of fee(s) under 37 CFR 1.16 and 1.17	<input checked="" type="checkbox"/> Credit any overpayments

FEE CALCULATION							
1. BASIC FILING, SEARCH, AND EXAMINATION FEES							
	FILING FEES		SEARCH FEES		EXAMINATION FEES		
		Small Entity		Small Entity		Small Entity	
Application Type	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fee (\$)	Fees Paid (\$)
Utility	300	150	500	250	200	100	
Design	200	100	100	50	130	65	
Plant	200	100	300	150	160	80	
Reissue	300	150	500	250	600	300	
Provisional	200	100	0	0	0	0	
2. EXCESS CLAIM FEES							
						Small Entity	
						Fee (\$)	Fee (\$)
Each claim over 20 (including Reissues)						50	25
Each independent claim over 3 (including Reissues)						200	100
Multiple dependent claims						360	180
Total Claims		Extra Claims	Fee (\$)	Fee Paid (\$)	Multiple Dependent Claims		
_____		_____	_____	_____	Fee (\$)		Fee Paid (\$)
_____		_____	_____	_____	_____		_____
Indep. Claims		Extra Claims	Fee (\$)	Fee Paid (\$)			
_____		_____	_____	_____			
_____		_____	_____	_____			
3. APPLICATION SIZE FEE							
If the specification and drawings exceed 100 sheets of paper (excluding electronically filed sequence or computer listings under 37 CFR 1.52(e)), the application size fee due is \$250 (\$125 for small entity) for each additional 50 sheets or fraction thereof. See 35 U.S.C. 41(a)(1)(G) and 37 CFR 1.16(s).							
Total Sheets	Extra Sheets	Number of each additional 50 or fraction thereof		Fee (\$)	Fee Paid (\$)		
_____	_____	_____ /50 _____ (round up to a whole number) x _____		_____	_____		
4. OTHER FEE(S)							
						Fees Paid (\$)	
Non-English Specification, \$130 fee (no small entity discount)							
Other (e.g., late filing surcharge): 1806 Submission of an Information Disclosure Statement							180.00

SUBMITTED BY			
Signature	<u>Colleen Superko</u>	Registration No. (Attorney/Agent)	39,850
Name (Print/Type)	Colleen Superko	Telephone	(617) 526-6000
		Date	December 15, 2005

Express Mail Label No. EV621477199US Dated: December 16, 2005



Express Mail Label No. EV621477199US Dated: December 16, 2005

Docket No.: 36119.140US3/AM100528
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Carl H. JUNE et al.

Application No.: 10/828,481

Confirmation No.: 4860

Filed: April 20, 2004

Art Unit: 1632

For: METHODS FOR TRANSFECTING T CELLS

Examiner: D. T. Nguyen

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This Information Disclosure Statement is being filed after the mailing date of the first Office Action on the merits and before the mailing date of a final Office Action or a Notice of Allowance.

Please charge the \$180.00 fee to our Deposit Account No. 08-0219.

Applicants request that the Examiner initial and return a copy of the enclosed Form PTO SB-08 with the next communication.

Dated: December 15, 2005


Respectfully submitted,

12/21/2005 DTESSEM1 00000024 080219 10828481

01 FC:1806 180.00 DA

By Colleen Superko
Colleen Superko

Registration No.: 39,850
WILMER CUTLER PICKERING HALE AND
DORR LLP
60 State Street
Boston, Massachusetts 02109
(617) 526-6000
Attorney for Applicants



PTO/SB/08a/b (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Application Number	10/828,481 – Conf. #4860
				Filing Date	April 20, 2004
				First Named Inventor	Carl H. JUNE et al.
				Art Unit	1632
				Examiner Name	D. T. Nguyen
Sheet	1	of	2	Attorney Docket Number	36119.140US3/AM100528

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
	AA*	US-5,272,082	12-21-1993	Santoli et al.	
	AB*	US-5,399,346	03-21-1995	Anderson et al.	
	AC*	US-5,443,983	08-22-1995	Ochoa et al.	
	AD*	US-5,733,543	03-31-1998	Nabel et al.	
	AE*	US-5,738,852	04-14-1998	Robinson et al.	
	AF*	US-5,827,642	10-27-1998	Riddell et al.	
	AG*	US-5,858,358	01-12-1999	June et al.	
	AH*	US-6,692,964	02-17-2004	June et al.	
	AI*	US-2004-0087025	05-06-2004	June et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				
	BA	WO-90/05541	05-31-1990	THE REGENTS OF THE UNIVERSITY OF MICHIGAN		
	BB	WO-94/12196	06-09-1994	TANOX BIOSYSTEMS, INC.		
	BC	WO-94/29436	12-22-1994	THE UNITED STATES OF AMERICA represented by THE SECRETARY OF THE NAVY		
	BD	WO-95/03408	02-02-1995	DANA-FARBER CANCER INSTITUTE		
	BE	WO-95/33823	12-14-1995	THE UNITED STATES OF AMERICA, represented by THE SECRETARY OF THE NAVY		
	BF	WO-95/34320	12-21-1995	REGENTS OF THE UNIVERSITY OF MINNESOTA		
	BG	WO-96/01122	01-18-1996	DANA-FARBER CANCER INSTITUTE		
	BH	WO-96/02646	02-01-1996	CYTOTHERAPEUTICS, INC.		
	BI	WO-96/06942	03-07-1996	MAX-PLANCK- GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V.		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. * CITE NO.: Those application(s) which are marked with an single asterisk (*) next to the Cite No. are not supplied (under 37 CFR 1.98(a)(2)(iii)) because that application was filed after June 30, 2003 or is available in the IFW. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

5412827

US1DOCS 5412827v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/828,481 – Conf. #4860
				Filing Date	April 20, 2004
				First Named Inventor	Carl H. JUNE et al.
				Art Unit	1632
				Examiner Name	D. T. Nguyen
Sheet	2	of	2	Attorney Docket Number	36119.140US3/AM100528

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	CA	Cann et al., "High Efficiency Transfection of Primary Human Lymphocytes and Studies of Gene Expression," <i>Oncogene</i> , 3:122-128 (1988)		
	CB	Coghlan, "Gene Dream Fades Away" <i>New Scientist</i> , 148: 14-15 (1995)		
	CC	Crystal, "Transfer of Genes to Humans: Early Lessons and Obstacles to Success" <i>Science</i> , 270:404-410 (1995)		
	CD	Fausser, "Long-Term Expression of Gene Introduction into Normal Human T-Lymphocytes by Retroviral-Mediated Gene Transfer," <i>Journal of Cellular Biochemistry</i> , 45:353-358 (1991)		
	CE	Finer et al., "kat: A High-Efficiency Retroviral Transduction System for PRimary HUman T Lymphocytes," <i>Blood</i> , 83(1):43-50 (1994)		
	CF	Guba et al., "Interleukin-3 Gene Induction in Normal Human T Cells Via Stimulation of CD3 and CD28," <i>Clinical Research</i> , 37(4) (1989)		
	CG	Gunzburg et al., "Virus Vector Design in Gene Therapy" <i>Molecular Medicine Today</i> , 410-417 (1995)		
	CH	Lowenthal et al., "Tumor Necrosis Factor α Induces Proteins that Bind Specifically to kB-like Enhancer Elements and Regulate Interleukin 2 Receptor α -chain Gene Expression in Primary Human T Lymphocytes," <i>PNAS USA</i> , 86:2331-2335 (1989)		
	CI	Mastrangelo et al. "Gene Therapy for Human Cancer: An Essay for Clinicians" <i>Seminars In Oncology</i> , 23(1):4-21 (1996)		
	CJ	Novak et al., "In Vitro Transfection of Fresh Thymocytes and T Cells Shows SUBset-Specific Expression of Viral Promoters," <i>Molecular and Cellular Biology</i> , 12:1515-1527 (1992)		
	CK	Park et al., "Transcriptional Regulation of Interleukin 3 (IL3) in Primary Human T Lymphocytes," <i>Journal of Biological Chemistry</i> , 268(9):6299-6308 (1993)		
	CL	Philip et al., "Efficient and Sustained Gene Expression in Primary T Lymphocytes and Primary and Cultured Tumor Cells Mediated by Adeno-Associated Virus Plasmid DNA Complexed to Cationic Liposomes," <i>Molecular and Cellular Biology</i> , 14:2411-2418 (1994)		
	CM	Tiberghien et al., "Ganciclovir Treatment of Herpes Simplex Thymidine Kinase-Transduced Primary T Lymphocytes: An Approach for Specific In Vivo Donor T-Cell Depletion After Bone Marrow Transplantation?" <i>Blood</i> , 84(4):1333-1341 (1994)		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

5412827